

Amendment
Attorney Docket No. S63.2-10062-US01

1. (Currently Amended) A medical device formed from a thermoplastic polymer composition, wherein the polymer composition ~~comprising a~~ is a melt mixture product of a melt mixture comprising

- at least one terminally reactive polymer, and
- a chain extender.


2. (original) A medical device as in claim 1 wherein the terminally reactive polymer has at least one terminal active hydrogen and/or carboxylic acid group thereon.

3. (original) A medical device as in claim 1 wherein the terminally reactive polymer is selected from the group consisting of polyesters; polyamides; polyurethanes; block copolymers incorporating a polyester, polyamide, polyurethane and/or polyether segment.

4. (original) A medical device as in claim 3 wherein the polymer composition further comprises a polymer selected from the group consisting of polyolefins, poly(meth)acrylate esters, silicones, and organic rubbers.

5. (original) A medical device as in claim 1 wherein the chain extender comprises a bis-lactam compound.

6. (original) A medical device as in claim 5 wherein the bis-lactam compound is represented by the following general formula (I):



Application No.
Page 3

Amendment
Attorney Docket No. S63.2-10062-US01

in which one or more of the methylene hydrogen atoms thereof may optionally be substituted by an alkyl or aryl radical; R represents a divalent organic radical; and n is an integer of 2 - 15.

7. (original) A medical device as in claim 6 wherein R is a group of formula (II), (III) or (IV):



where A is a divalent hydrocarbon group, which is optionally interrupted by one or more ether oxygen atoms;



where B is -NH-A-NH-, and A is as defined for formula II; and



8. (original) A medical device as in claim 5 wherein the bis-lactam compound is employed in said melt mixture product in an amount of from about 0.1 % to about 5% by weight of the terminally reactive polymer.

9. (original) A medical device as in claim 5 wherein the bis-lactam compound is a member selected from the group consisting of N,N'-isophthaloyl bis-caprolactam, N,N'-adipoyl


Application No.
Page 4

Amendment
Attorney Docket No. S63.2-10062-US01

bis-caprolactam, N,N'-terephthaloyl bis-lauro lactam, N,N'-isophthaloyl bis-butyrolactam, carbonyl bis-caprolactam and mixtures thereof.

10. (original) A medical device as in claim 1 wherein the chain extender comprises a bis-oxazoline and/or bis-oxazine compound.

11. (original) A medical device as in claim 10 wherein the bis-oxazoline and/or bis-oxazine compound is represented by the formula (VI):



where X is a divalent hydrocarbon group and the rings thereof are 5-membered rings for the bisoxazoline or 6-membered rings for the bisoxazine, respectively; n = 0 or 1; and D is a divalent organic group.

12. (original) A medical device as in claim 10 wherein the bisoxazoline and/or bisoxazine compound is a member selected from the group consisting of 2,2'-bis(2-oxazoline), 2,2-bis(4-methyl-2-oxazoline), 2,2'-bis(4-phenyl-2-oxazoline), 2,2'-bis(4-hexyloxazoline), 2,2'-p-phenylene bis(2-oxazoline), 2,2'-m-phenylene bis(2-oxazoline), 2,2'-tetramethylene bis(4,4'-dimethyl-2-oxazoline) 2,2'-bis(2-oxazine), 2,2-bis(4-methyl-2-oxazine), 2,2'-bis(4-phenyl-2-oxazine), 2,2'-bis(4-hexyloxazine), 2,2'-p-phenylene bis(2-oxazine), 2,2'-m-phenylene bis(2-oxazine), 2,2'-tetramethylene bis(4,4'-dimethyl-2-oxazine) and mixtures thereof.

Application No.
Page 5

Amendment
Attorney Docket No. S63.2-10062-US01

13. (original) A medical device as in claim 10 wherein the bis-oxazoline and/or bis-oxazine compound is employed in said melt mixture product in an amount of from about 0.1 % to about 4% by weight of the terminally reactive polymer.
14. (Cancelled)
15. (original) A medical device as in claim 1 wherein the device is a catheter or a catheter balloon.
16. A medical device as in claim 1 wherein the chain extender is incorporated into said melt mixture product in an amount which increases polymer molecular weight but does not substantially promote or induce crosslinking.
17. (Currently Amended) A method of preparing a medical device balloon comprising extruding a polymer composition to form tubing and blowing a segment of the tubing to form the balloon, wherein the polymer composition ~~comprising a~~ is a melt mixture product of a melt mixture comprising
- a) at least one terminally reactive polymer and
 - b) a chain extender.
18. (original) A method as in claim 17 wherein the terminally reactive polymer has at least one terminal active hydrogen and/or carboxylic acid group thereon.
19. (original) A method as in claim 17 wherein the terminally reactive polymer is selected from the group consisting of polyesters; polyamides; polyurethanes; block copolymers incorporating a polyester, polyamide, polyurethane and/or polyether segment.
20. (original) A method as in claim 19 wherein the polymer composition further comprises a polymer selected from the group consisting of polyolefins, poly(meth)acrylate esters, silicones, and organic rubbers.

Application No.
Page 6

Amendment
Attorney Docket No. S63.2-10062-US01

21. (original) A method as in claim 17 wherein the chain extender comprises a bis-lactam compound.
22. (original) A method as in claim 21 wherein the bis-lactam compound is employed in said melt mixture product in an amount of from about 0.1 % to about 5% by weight of the terminally reactive polymer.
23. (original) A method as in claim 21 wherein the bis-lactam compound is a member selected from the group consisting of N,N'-isophthaloyl bis-caprolactam, N,N'-adipoyl bis-caprolactam, N,N'-terephthaloyl bis-lauro lactam, N,N'-isophthaloyl bis-butyrolactam, carbonyl bis-caprolactam and mixtures thereof.
24. (original) A method as in claim 17 wherein the chain extender comprises a bis-oxazoline and/or bis-oxazine compound.
25. (original) A method as in claim 24 wherein the bisoxazoline and/or bisoxazine compound is a member selected from the group consisting of 2,2'-bis(2-oxazoline), 2,2-bis(4-methyl-2-oxazoline), 2,2'-bis(4-phenyl-2-oxazoline), 2,2'-bis(4-hexyloxazoline), 2,2'-p-phenylene bis(2-oxazoline), 2,2'-m-phenylene bis(2-oxazoline), 2,2'-tetramethylene bis(4,4'-dimethyl-2-oxazoline) 2,2'-bis(2-oxazine), 2,2-bis(4-methyl-2-oxazine), 2,2'-bis(4-phenyl-2-oxazine), 2,2'-bis(4-hexyloxazine), 2,2'-p-phenylene bis(2-oxazine), 2,2'-m-phenylene bis(2-oxazine), 2,2'-tetramethylene bis(4,4'-dimethyl-2-oxazine) and mixtures thereof.
26. (original) A method as in claim 24 wherein the bis-oxazoline and/or bis-oxazine compound is employed in said melt mixture product in an amount of from about 0.1 % to about 4% by weight of the terminally reactive polymer.

Application No.
Page 7

Amendment
Attorney Docket No. S63.2-10062-US01

27. (original) A method as in claim 17 wherein the chain extender is incorporated into said melt mixture product in an amount which increases polymer molecular weight but does not substantially promote or induce crosslinking.
28. (cancelled)
29. (Currently Amended) A method of preparing a medical device comprising forming at least a portion of the device from a thermoplastic polymer composition, wherein the polymer composition ~~comprising a~~ is a melt mixture product of a melt mixture comprising
- a) at least one terminally reactive polymer, and
 - b) a chain extender.
30. (original) A method as in claim 29 wherein the terminally reactive polymer has at least one active hydrogen and/or carboxylic acid group thereon.
31. (original) A method as in claim 29 wherein said step of forming at least a portion of the device from a thermoplastic polymer composition comprises extruding a tube of said polymer composition.
32. (original) A method as in claim 31 wherein the medical device is a catheter or a balloon.
33. (original) A method as in claim 29 wherein the medical device is a balloon, the method further comprising blowing a segment of the extruded tube at an elevated temperature and pressure to form the balloon.
32. (original) A method as in claim 29 wherein the chain extender is incorporated into said melt mixture product in an amount which increases polymer molecular weight but does not substantially promote or induce crosslinking.

Application No.
Page 8

Amendment
Attorney Docket No. S63.2-10062-US01

33. (Previously Presented) A method as in claim 31 wherein said tubing is extruded from an extruder and said melt mixture product is prepared in the extruder.

34. (Previously presented) A method claim 17 wherein said tubing is extruded from an extruder and said melt mixture product is prepared in the extruder.